IMB-808

IMB-808 is a potent LXRα/β dual agonist with EC50 values of 0.53 μM and 0.15 μM (0.15 μM, using GAL4-pGL4-luc reporter plasmid) for LXRβ and LXRα, respectively. IMB-808 promotes expression of genes related to reverse cholesterol transport (ABCA1 and ABCG1) . IMB-808 can be used as a promising agent for the prospective treatment of atherosclerosis research[1].

Product Specifications

CAS Number

[870768-70-0]

UNSPSC

12352005

Target

LXR

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/imb-808.html

Concentration

10mM

Purity

99.85

Solubility

DMSO : 250 mg/mL (ultrasonic)

Smiles

O=C(N(CC(NC1=CC=C(C(F)=C1F)F)=O)C)C2=CC=C3OCCOC3=C2

Molecular Formula

C18H15F3N2O4

Molecular Weight

380.32

References & Citations

[1]Duo Lu, et al. Identification of a Novel Liver X Receptor Agonist that Regulates the Expression of Key Cholesterol Homeostasis Genes with Distinct Pharmacological Characteristics. Mol Pharmacol. 2017 Apr;91 (4) :264-276.